Deals Of The Week Looks At 2014 Takeout Targets

The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.

The momentum for biotech initial public offerings has lessened the urgency for private companies to rely on deal-making as an exit strategy, but M&A remains one of the best ways to boost the stock price of public companies – both those being acquired and those acquiring – and for public investors to make a significant return on their investments.

A research report recently released by Leerink Partners analyst Joseph Schwartz predicts the top 10 takeout targets of 2014 and early 2015, with Alkermes PLChigh on the list. It...

More from Archive

More from Pink Sheet